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ABSTRACT 
RNA interference (RNAi) is a post-transcriptional gene silencing mechanism preserved during evolution. This mecha-
nism, recently described, is mediated by small double-stranded RNAs (dsRNAs) that can specifically recognize a target 
mRNA sequence and mediate its cleavage or translational repression. The use of RNAi as a tool for gene therapy has 
been extensively studied, especially in viral infections, cancer, inherited genetic disorders, cardiovascular and rheumatic 
diseases. Together with data from human genome, the knowledge of gene silencing mediated by RNAi could allow a 
functional determination of virtually any cell expressed gene and its involvement in cellular functioning and homeos-
tasis. Several in vitro and in vivo therapeutic studies with autoimmune disease animal models have been carried out 
with promising results. The pathways of tolerance breakage and inflammation are potential targets for RNAi therapy in 
inflammatory autoimmune diseases. This review will present the basic principles of RNAi and discuss several aspects 
of RNAi-based therapeutic approaches, from in vitro tool design and target identification to in vivo pre-clinical drug 
delivery, and tests of autoimmune diseases in human cells and animal models. Finally, this review will present some 
recent clinical experience with RNAi-based therapy.
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INTRODUCTION
RNA interference (RNAi) is a cellular mechanism respon-
sible for post-transcriptional gene silencing (PTGS) acting 
on messenger RNA (mRNA). In the heart of this mechanism 
there is a double stranded RNA molecule (dsRNA) that, when 
incorporated in active form to an intracytoplasmic complex, 
binds to a complementary sequence of nucleotides located in 
mRNA target, thus, causing silencing by inhibiting translation 
and or mRNA degradation. There is evidence that dsRNAs are 
also involved with the maintenance of condensed chromatin 
regions and suppression of transcription in these regions vi-
cinity. However, the association between transcription gene 
silencing (TGS) and RNAi is not yet completely understood. 
In fungi, the deletion of genes related to RNAi pathway causes 
loss of gene silencing and heterochromatin disruption. This 
phenomenon is not well understood at molecular level, but 
seems to have great importance to the proper functioning of 
genes and maintenance of genomic integrity.1
RNAi was first described in plants (petunias) in the early 
1990s.2 Transgenic plants, overexpressing genes for pigment 
production, presented white flowers due to pigment synthesis 
inhibition, caused by coordinate silencing of both transgene 
and endogenous gene. This phenomenon, known as “co-
suppression” was also observed in other species of plants, 
fungi, and other organisms, but the mechanism leading to gene 
silencing was still unknown.2-4
In 2006, the American researchers Andrew Z. Fire and 
Craig C. Mello were awarded the Nobel Prize in Physiology 
and Medicine for participating in the elucidation of gene 
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silencing by RNAi.5 The mechanism occurs in many eukaryotic 
organisms,6,7 and the dsRNAs involved can be classified ac-
cording to their origin and function in at least three categories: 
miRNAs (microRNAs), siRNAs (short interfering RNAs), and 
shRNAs (short hairpin RNAs).8
MiRNAs represent endogenous small dsRNAs, appro-
ximately 22 nucleotides long, whose main function is to act as 
post-transcriptional silencer by inhibiting translation of target 
mRNA into protein. They were discovered just over a decade ago, 
in studies of Caenorhabditis elegans, and are now recognized as 
key regulators of gene expression in plants and animals. Genes 
that encode miRNAs are transcribed by RNA polymerase II in a 
long primary microRNA (pri-miRNA) that, inside the nucleus, 
is cleaved by a protein complex which comprises an RNase III 
(Drosha) and Pasha or DGCR8 protein (DiGeorge Syndrome 
Critical Region 8 protein) with a binding domain for dsRNA. The 
cleavage results in a precursor micro-RNA (pre-miRNA), with 
approximately 70 base pairs, containing a double stranded stretch 
and a single-stranded loop, forming a structure called hairpin. Pre-
miRNA is exported to cytoplasm by exportin-5, and is cleaved 
by Dicer, generating a mature miRNA of about 22 nucleotides in 
length. Dicer is a RNase III essential in the process of RNAi. It 
presents a RNA binding domain, PAZ, which seems responsible 
for the size of generated dsRNA. Dicer is also involved in the 
incorporation of one miRNA strand into a complex called RNA-
Induced Silencing Complex (RISC), to which it belongs together 
with Argonaut (Ago2) and other proteins.9 RISC complex allows 
pairing between miRNA incorporated strand and target mRNA 
homologous region by complementary base pairing. Normally, 
when complementarity is total, mRNA degradation occurs, and 
when it is partial, translation repression and subsequent mRNA 
degradation occur (Figure 1).10
Argonauts are proteins present in RISC complex, characte-
rized by the presence of conserved domains (PAZ and Piwi). 
They bind to siRNA and miRNA, and have endonuclease activity 
directed against the mRNA strand complementary to siRNA or 
miRNA. Argonaut proteins are also responsible for selecting 
the siRNA strand, which will be incorporated into RISC.11,12
The shRNAs are double-stranded RNAs built to present a 
similar structure to miRNAs. They can be exogenously synthe-
sized and introduced into the cell or transcribed inside the cell 
from vectors encoding the shRNA linked to a RNA polymerase 
III promoter. In this case, the transcript is processed by Dicer 
in the same way as miRNAs.13
The siRNA molecules are synthetic double-stranded RNA 
of 19 to 30 pb, acting through the pairing of complementary 
sequences to mRNA target messenger, causing its degradation 
and therefore specific gene silencing. Target gene silencing 
provides information about which function the protein coded 
by this gene  performs in the cell.14
Recently, the existence of a link between RNAi and GW 
bodies (GWB) has been established,15,16,17 GWBs seem to be the 
sites involved in mRNA translation repression by miRNAs. The 
GWB (or P-bodies) are recently described cytoplasmic structures 
involved in post-transcriptional control of gene expression.18 
This control regulates turnover of mRNA, removal of aberrant 
RNAs, and nonsense mutations. GWB formation seems to 
depend on specific proteins and RNA, particularly miRNAs.15
Figure 1. Chart of the pathways leading to interference by 
microRNAs and siRNAs.
Figure 2. Immunofluorescence on HEp-2, showing presence 
of GW bodies (visualized in green) in cytoplasm. The nuclei 
were stained with DAPI (blue). Photomicrograph courtesy 
of Dr. EK Chan, Department of Oral Biology, University of 
Florida, Gainesville, USA.
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General aspects related to therapy using RNAi
The great potential of RNAi has resulted in successful stra-
tegies for silencing a wide variety of protein-coding genes, 
providing important information about gene function and coded 
proteins. The high specificity of this method allows interfering 
with disease-related alleles, which differ from normal allele 
by only in a few nucleotides. RNAi is much more potent than 
other antisense strategies that use short antisense strands of 
DNA and ribozymes.19
RNAi has been the method of choice for gene silencing 
in mammalian cells due to its selectivity and potency. Use of 
RNAi as a therapeutic approach has been considered highly 
promising in fighting diseases in which abnormal expression 
of certain genes can be identified as the cause or contributing 
factor. Among these diseases, we can mention cancer, dominant 
genetic disorders, autoimmune diseases, and viral infections.20
There are currently over a dozen biotechnology companies 
dedicated to developing clinical applications of siRNA in 
several human diseases.21 RNAi has been used successfully 
in experimental models for silencing genes critical for tumor 
cells viability, proliferation, and spread.22,26 So far, however, 
the greatest contribution of RNA interference has been the 
technological revolution introduced in the process of new drug 
discovery. The use of RNAi reduces the number of potential 
targets, allowing us to centralize efforts on most promising 
genes.27,28 RNAi has also become a powerful tool for validation 
of drug therapy targets.
siRNAs and shRNAs
There are basically two strategies to induce RNAi. In the 
first, pre-synthesized siRNAs are introduced into target cells. 
Although many strategies apply siRNAs of 21-23 base pairs, 
the longer siRNAs with 27 nucleotides (nt), which are proces-
sed by Dicer, are more effective in promoting silencing. These 
longer siRNAs have a 3’ end with 2nt unpaired and a blunt 
end allowing that Dicer cleavage results in a single siRNA. 
Eventually, the blunt end may activate signaling proteins and 
induce unwanted production of interferon by stress response 
pathways, however, being more powerful, the 27nt siRNAs 
can be used in smaller doses, avoiding this effect.29 Because 
the silencing attained with siRNAs is transient, new strate-
gies were developed to obtain a more permanent silencing. 
The second strategy is based on the introduction of vectors 
encoding-shRNA, resulting in stable, long-term cell silencing. 
shRNA transcription is controlled by RNA polymerase II or 
III promoter sequences, depending on the desired expres-
sion. High levels of shRNAs are obtained with RNA pol III 
promoters. The shRNAs, controlled by RNA pol II promoters 
and transcribed as long precursors that mimic pri-miRNAs, 
can be specifically expressed in a particular tissue and, because 
they are effective at low levels, they avoid saturation of RNAi 
pathway components.20,29
Selection
There are three important attributes that should be taken into 
consideration when selecting a siRNA: potency, specificity, 
and nuclease stability. The initial step to identify good siR-
NAs candidates start with a bioinformatics project. Several 
algorithms have been developed to select siRNAs with the 
specificity and stability characteristics desired, and currently 
there are in vitro methods to quickly identify candidates capable 
of silencing a particular gene of interest.30 Still, siRNAs must 
be evaluated experimentally to determine the efficacy of gene 
silencing and verify the absence of unwanted effects, named 
off-target effects.31
Potency
siRNAs can be designed to silence any desired gene, often 
with in vitro activity in nanomolar or lower concentrations. 
Although the use of algorithms increases the chance of iden-
tifying effective siRNAs, sometimes, it fails to provide potent 
siRNAs.30 A bit longer siRNAs, which need to be processed by 
Dicer before being incorporated into RISC complex, seems to 
result in greater efficiency. However, these longer molecules 
are more difficult to synthesize and more likely to activate an 
unwanted immune response. 31
Specificity
One of the critical factors for successful RNAi use is the siRNA 
ability to silence specific mRNA target. The siRNA-mediated 
gene silencing can be highly specific, as evidenced by selective 
silencing of alleles that differ in a single nucleotide.32 However, 
siRNAs can also recognize and interfere with the expression 
of mRNAs with partial homology to target mRNA. In fact, the 
assessment of transcriptional activity in vitro has shown that 
siRNAs can alter the mRNA levels of genes that are not an 
intended target (off-target effect), though with less intensity.33,34 
A careful design of siRNA molecule and the introduction of 
chemical modifications on guide strand ribose residue can re-
duce or prevent most of the so-called off-target effects without 
affecting siRNA performance on desired gene.35
Furthermore, siRNAs may eventually induce undesired 
effects by activating the innate immune response mechanisms 
used in viral defense. Activation of Toll-like receptors (TLR), 
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particularly TLR7 which recognizes dsRNA, is a major 
concern. The activation of these receptors on plasmacytoid 
dendritic cells results in production of type I interferons and 
proinflammatory cytokines.36
Stability
Unprotected siRNA molecules are degraded in human plasma, 
with a half-live of minutes.3738 To convert siRNAs into opti-
mized drug, chemical modifications with the ability to extend 
molecule half-life without affecting its biological activity have 
been thoroughly investigated.
Some changes involve phosphate group alterations of linka-
ge between nucleotides, which confer exonuclease stability 
and are well tolerated.37-40 Changes in sugar residues, such as 
methylation, which confer resistance to endonuclease, although 
generally tolerated, depend on location within molecule. In 
general, changes in sugar sense strand are better accepted than 
in guide strand, or antisense.21,4
The minimum changes necessary for stability of a given 
siRNA can be assessed by the study of siRNA degradation 
products in plasma. Some groups had stability and efficiency 
improvements of in vivo deliver complexing siRNA with 
cholesterol,42 atelocolgen,43 and polietilenimina.43
Introduction of siRNAs in vivo
The main obstacle for using siRNAs as therapeutic drugs is to 
achieve its penetration into cell via cytoplasmic membrane to 
incorporated it into the RNAi pathway and cause degradation 
of target mRNA in selected tissue. In the absence of trans-
fection agents or high pressure, most cells do not incorporate 
siRNA.45,46 
Due to its negative charge, siRNA does not penetrate easily 
through hydrophobic cell membranes.20,47 However, silencing 
in vivo has been reported after direct administration of naked 
siRNAs to anatomically isolated sites (intravitreal, intranasal, 
and intrathecal), showing the possibility of delivering siRNAs 
into eyes, lungs, and central nervous system.48,51 However, 
the therapeutic use of RNAi in a broader sense depends on 
whether siRNA molecules can be associated with other phar-
macological properties such as bioavailability and selectivity 
for target cells.31,42
Several approaches use intravenous injection of chemi-
cally modified siRNAs, through cholesterol conjugation, or 
protected within cationic liposomes. Cholesterol conjugation 
has shown good results, because it prolongs siRNA half-life 
in circulation by binding to lipoproteins, which are resistant to 
kidney filtration and also offer protection to action of plasma 
nucleases. Although effective, cholesterol conjugation is not 
a selective method, because cholesterol-siRNA-complex 
can be endocytosed by cholesterol receptors found in all cell 
types.20 Cationic liposome binding to siRNAs, which has also 
been widely studied, improved pharmacokinetics and reduced 
siRNAs toxicity, although it will also result in broad spectrum 
of cellular action.31 
Selective mechanisms for siRNA delivery to cells and 
tissues are being intensively studied. One possibility is the 
binding of siRNAs to aptamers that bind to specific cell 
receptors. Aptamers are RNA or DNA molecules capable 
of binding with high affinity to ion, oligosaccharides, and a 
large variety of proteins and glycoproteins, such as thrombin, 
L-selectin, P-selectin, vasopressin. Besides having high affinity 
and specificity for their ligands, aptamers can be chemically 
synthesized, and is therefore very attractive for therapeutic 
use, where quality control is critical.52
The introduction of cell-specific siRNAs using siRNA 
bound to a fusion protein of immunoglobulin-protamine Fab 
was recently reported. The binding of siRNA is mediated by 
interaction with the protamine portion, and cellular specifi-
city is dependent on the Fab portion of antibody molecule.45 
The delivery to specific cells facilitates siRNA incorporation 
by endocytosis. Several groups have studied the use of viral 
vectors to introduce shRNAs into organisms.53,54 However, the 
use of viral vectors is still questioned regarding therapeutic 
use safety.55
Preclinical studies with RNAi in 
autoimmune rheumatic diseases
The last three decades were marked by rapid advances in mo-
lecular biology techniques, which are now widely available for 
routine research groups worldwide. Clear examples include mi-
croarray and methods of gene silencing as the small interfering 
RNAs (siRNA) and cell transfection with antisense constructs. 
For research groups interested in studying disease pathogenesis, 
these new techniques enable rapid screening of genes that are 
expressed in different ways both in health and disease and are 
probably involved in disease onset and progression.56 In this 
context, much progress has been made in understanding the 
pathophysiology of connective tissue diseases. These diseases 
comprise a broad spectrum of disorders in which the pathophy-
siology and clinical presentation are quite different. However, 
discovery of key mechanisms and molecules involved in con-
nective tissue disease pathogenesis have significantly increased 
treatment options for its systemic and organ-specific complica-
tions. While conventional non-selective therapies do not, yet, 
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have importance daily in clinical setting, the majority of new 
agents developed focus on specific molecules or mechanisms 
that have a functional role in systemic disease pathogenesis or 
organ-specific manifestations. Several cytokines, chemokines, 
transcription factors, and molecules expressed on immune cell 
surface (CDs, adhesion molecules) have been investigated for 
molecular therapy with RNAi.
Regarding osteoarthritis (OA), a number of cytokines 
and enzymes have been associated with joint damage and, 
in recent years, gene therapies aimed at cytokines and/or 
signaling pathways, activated in inflammatory processes, 
have brought new hope for treatment. IL-1 and TNF-α are 
considered the main inflammatory cytokines taking part in 
this disease. 57 Therefore, they are potential targets for OA 
therapy. NF-κB is one of the key transcription factors asso-
ciated with inflammatory pathway, and various methods have 
been used to inhibit the induction of NF-κB, such as the use 
of antisense oligonucleorides58 and adenoviral constructs of 
mutated IkB.59 Recently, a study of OA in animal model has 
shown the efficacy of siRNA specific for NF-κB p65 subunit.60 
RNA interference was able to inhibit the expression of several 
genes related to NF-κB signaling pathway, such as genes of 
cyclooxygenase-2 (COX-2), nitric oxide synthase-2 (NOS-2), 
and matrix metalloproteinase-9 (MMP-9). These mediators are 
associated with initial progression of joint damage in osteoar-
thritis model and are induced in chondrocytes exposed to IL-1 
and TNF-α. These results demonstrate that siRNA specific for 
NF-κB p65 is a potential candidate in preventive gene therapy 
for early stage OA.
The ability to inhibit NF-κB activity becomes even more 
interesting when its power of action on immune cell activation 
is broadly examined, as in some protocols that seek to inhibit 
maturation of dendritic cells and thus restore the immune 
tolerance. The Canadian biotechnology company Tolerothech 
Inc. has explored the use of siRNA in preclinical studies to 
silence inflammatory Th1 pathway. This company developed 
the drug ToleroVaxT, which is a siRNA specific for IL-12 p35 
subunit. ToleroVaxT use induces immune deviation from Th1 
response to Th2 response with high levels of IL-4 and IL-10 
and low FNI-g production. Inhibition of dendritic cells (DCs) 
allostimulatory activity in mixed cultures of leukocytes became 
possible with this tool.61
Because age is considered another risk factor for OA deve-
lopment, chondrocytes senescence has also been investigated 
with siRNA, for its correlation with decreased extracellular 
matrix synthesis by chondrocytes that also show less responsi-
veness to growth factors. The p16INK4a protein has an important 
role in cell cycle control and senescence by acting as a cyclin 
competitor that control cell output of G1 phase and leading to 
senescence. OA patients show high expression of p16INK4a, and 
in vitro silencing of this protein in chondrocytes from patients 
with OA led to a change in their characteristics senesced, 
increased expression of some chondrocyte-specific genes, 
and overall improvement in their repair ability. Inhibition of 
p16INK4a by RNAi can be exploited in a therapeutic strategy for 
blocking senescence of articular chondrocytes relevant to OA 
treatment and prevention.62 
SiRNA therapeutic strategies have also been investigated 
in vitro in synovial cells of rheumatoid arthritis (RA). One 
of the mechanisms causing joint degradation in RA is the 
presence of synovial cells abnormally resistant to apoptosis, 
which produce high levels of proinflammatory cytokines 
and metalloproteinases. Induction of apoptosis is a common 
property of death receptors, most of them belonging to the 
family of tumor necrosis factor (TNF). However, some kinds 
of TRAIL receptors, as TRAIL 4, have antiapoptotic activity. 
In a study by Terzioglu et al. (2007), it was observed that 
gene therapy using siRNA specific for TRAIL 4 combined 
with pro-apoptotic TRAILS transfection cleared synoviocytes 
resistant to apoptosis. These receptors expression balance may 
be a new gene therapy strategy to sensitize synoviocytes from 
RA patients to apoptosis.63 In collagen-induced arthritis animal 
models, some studies with siRNA targeting TNF-α silencing 
are being conducted. Some forms of RNAi delivery are being 
tested, such as siRNA direct delivery by electroporation in joint 
tissue, or siRNA systemic delivery using liposome as carrier. 
Both studies are showing good results, significantly decreasing 
joint inflammation.64,65
Regarding systemic lupus erythematosus (SLE) diseases, 
studies in animal models have demonstrated the potential of 
RNAi therapy. Mice homozygous for mutation in the gene 
encoding Roquin protein show a great increase in receptor 
expression of inducible co-stimulating T cells (ICOS), with 
consequent lymphocytes accumulation and development of 
a syndrome similar to SLE.66 Roquin protein contains RNA 
binding domains and may be observed in association with 
stress granules and GW-bodies. This close association leads 
to questions on the possibility of Roquin being able to direct 
some mRNAs to a decay route by miRNA in GW-bodies. The 
miR-101 is a key component in suppressing the expression of 
ICOS, and the expression of miR-101 was able to reduce the 
levels of co-stimulatory receptor. It is believed that, due to a 
mutation in mice Roquin protein, the mRNA of ICOS is not 
properly addressed to GW-bodied, which prevents their expres-
sion control by miR-101.66 There are many studies showing 
the importance of proteins able to regulate miRNA-mediated 
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repression, directing target mRNA location to GW-bodies. 
Interestingly, a large number of autoantibodies against key 
components of RNA interference machinery have been des-
cribed, both in mice and in humans,67 including autoantibodies 
against Argonaut proteins and Dicer.68
In autoimmune diseases with fibrosis clinical manifestations, 
such as systemic sclerosis, TGF-β1 is a potential target for tre-
atment and prevention. Because this cytokine has an important 
role in fibrosis pathophysiology of various diseases, the use of 
RNAi targeting this molecule may prevent fibrosis development 
or even improvement of this condition, as noted in the study by 
Takabatake et al. (2005) of glomerulonephritis animal model. In 
this study, the use of siRNA against TGF-β1 led to a significant 
improvement in fibrotic matrix progression and expansion.69
The profile analysis of miRNA expression has also proved 
to be a useful tool in investigating the genetic mechanisms 
involved in the predisposition and pathogenesis of human dise-
ases, since they have an essential role in embryogenesis and cell 
differentiation. Koralov et al. (2008) showed a role of miRNAs 
in the early stages of B cell development in experimental model 
of conditional Dicer knockout.70 Dai et al. (2008) studied the 
expression profile of miRNA in SLE patients, and identified 
16 miRNAs differentially expressed in SLE group compared 
with normal controls,71 indicating that miRNAs assessment is a 
potentially useful biomarker tool of probable factors involving 
autoimmune rheumatic diseases pathogenesis.
Perspectives
Although therapy with RNAi treatment is associated with a 
high degree of specificity, recent findings suggest that off-
target effects and other potential complications can be noted. 
Some siRNA may induce post-translational suppression of 
unwanted gene products, as observed by miRNAs activity, 
which may have the ability to act on different gene products. 
This inhibitory effect occurs when non-specific siRNA is used 
in low concentrations and presents partial complementarity 
with target gene.
The development of siRNA with a simple change that will 
lead to a partial matching can not only reduce the efficiency of 
silencing, but increase the chance of pairing with transcripts 
whose silencing is not wanted and have regions of partial 
complementarity. Other nonspecific effects of siRNAs have 
also been observed. For example, alternative pathways of 
cellular response against dsRNA can be activated; resulting 
in activation and increased expression of genes typically 
associated with innate immune response, including genes for 
type I interferon (INF) gene expression.36 In addition, toll-like 
receptor (TLRs), as TLR7 and TLR8, may recognize certain 
sequences of siRNA and induce immune response with INF 
production.36 Further studies will be needed to investigate the 
frequency of nonspecific recognition and adverse effects of 
using RNAi and shRNA, as well as to identify the structural 
sequences responsible for causing such processes. Potential 
strategies to reduce induction of IFN effects or TLRs activation 
include developing algorithms for siRNAs design and chemi-
cal modifications capable of reducing their immunogenicity 
and extend their lifetime, preventing degradation by RNases. 
Another possibility that should be closely investigated relates 
to safety with regard to possible mutagenesis insertion and 
malignant transformation, or the possibility of immune res-
ponses development against proteins of viral vectors used for 
transfection in some therapy models.34 In general, the use of 
RNAi as a therapeutic strategy is an attractive alternative and 
potentially promising. The results of experimental models of 
autoimmune disease and in vitro studies with human cells have 
been encouraging, but this therapeutic model future clinical 
application still requires vigorous investigations of efficacy, se-
lectivity; development of strategies to avoid off-target effects; 
and system optimization for siRNAs delivery. 
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